Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards

Life Health > Health Insurance > Health Insurance

Fed fears PPACA could control costs

Your article was successfully shared with the contacts you provided.

(Bloomberg) – The low rate of inflation is making the Federal Reserve Board nervous, and part of the problem is the sluggish rate of increase in health care costs.

Consumers would normally think that controlling health care costs is a good thing.

But, from the perspective of Federal Reserve Chair Janet Yellen and colleagues who are thinking about raising interest rates, the health care cost slump is one of the factors suggesting that they should keep rates at record low levels.

Price increases, not counting volatile food and energy costs, decelerated to a 1.1 percent year-over year pace in February. from 2 percent two years earlier, with medical goods and health-care services accounting for almost a third of the slowdown, according to government personal consumption exemption (PCE) data analyzed by Bloomberg.

The cost of health-care services rose just 0.8 percent in February from a year earlier, compared with an average 2.6 percent pace in the previous 10 years.

Prices of medical goods such as prescription drugs rose 2.2 percent, down from the 10-year average of 2.7 percent.

Behind the slowdown in medical costs: cuts in Medicare reimbursements under last year’s budget sequestration, and an influx of cheaper generic drugs as patents expired on brand-name prescription medications.

Downward pressure on health costs may ease this year, because fewer patents are expiring.

Still, that won’t be enough to lift overall price increases to the Fed’s 2 percent goal.

“It’s going to be a slow grind for medical care this year overall,” said Omair Sharif, an economist at RBS Securities Inc. in Stamford, Connecticut. Health-care inflation levels are “not going back to the pre-recession days.”

The Fed, which conquered runaway inflation in the 1980s under Paul Volcker’s chairmanship, is now trying under Yellen to head off what many economists believe to be another problem, persistent disinflation.

Yellen has said that policy makers believe that a lack of inflation could “pose risks to economic performance.”

Low interest rates hurt retirement savers and insurance lines that create long-term claim payment obligations, such as long-term disability insurance and long-term care insurance.

But many economists say low inflation rates make it harder for borrowers to pay off debts and for businesses to boost profits.

Investors are showing doubts about whether the Fed will succeed in rekindling inflation and are moving money out of exchange-traded funds tracking U.S. inflation. Traders pulled $524.6 million in the five days ended April 7 from the iShares TIPS ETF, the largest fund tracking Treasury Inflation Protected Securities. That erased all of the inflation bets accumulated in March, when the fund saw inflows of $326.8 million.

February’s 1.1 percent core PCE reading matched January’s as the lowest since March 2011. Including volatile food and energy costs, PCE inflation, the Fed’s preferred gauge, was even weaker, slowing to a 0.9 percent year-over-year pace, less than half the Fed’s 2 percent goal.

“If inflation is persistently running below our 2 percent objective, that is a very good reason to hold the funds rate at its present range for longer,” Yellen said at a March 19 press conference.

The Fed’s target for the federal funds rate has been at zero to 0.25 percent since December 2008

What will PPACA do?

Health-care costs, which make up almost a quarter of the core PCE gauge, will stay on a slow course this year, according to Bloomberg survey of 24 economists conducted April 1-3. That’ll make it even tougher for inflation figures to justify tightening monetary policy.

Sixty-three percent of the economists surveyed see health inflation rising in 2014 at a pace that’s short of historical averages, with an additional 8 percent projecting health-care costs will fall.

Price increases for medical services, which make up the biggest share of health costs, have eased in the past two years.

The rate of increase fell to 0.2 percent, from 1.6 percent in February 2012, for physician fees, and to 0.3 percent, from 1.8 percent, for nursing home care costs.

Economists have yet to see the Patient Protection and Affordable Care Act (PPACA) leading to any increase in health care costs.

PPACA coverage expansion provisions could help the Fed, economists say.

“We’re covering more people with insurance, and therefore presumably lifting the demand for health care, and there’s no corresponding rise in the supply of health care,” said Dean Maki, chief U.S. economist for Barclays Plc in New York and a former Fed economist. While that’s a “modest positive” for medical inflation, he said, “what’s more difficult is to weigh the broader impact of the Affordable Care Act.”

Medicare program actuaries reported earlier this year that they see Medicare enrollee hospitalization cost trends falling.

This week, Medicare officials said their actuaries now believe the drop is bigger than they originally thought. Officials built the cost trend shift into their 2015 Medicare Advantage plan bid solicitation documents.

If insurance companies follow the Medicare program’s lead, “what you end up seeing is lower reimbursement rates to hospitals and physicians for all kinds of health-care procedures,” Sharif said. “To me, that’s been the biggest aspect of the slowing pace.”

Also weighing on health-care costs is a surge in patent expirations for brand-name prescription drugs that has led to a flood of generics entering the market and driving down prices.

In 2012 alone, drug sales lost due to expiring patent protection totaled $24 billion, almost 10 times the amount in the prior year, according to data from eight major drugmakers compiled by Bloomberg Industries. This year those companies are projected to lose another $14 billion in sales to generic competition.

Consumers see the impact in lower copays as generics are substituted for name-brand drugs. The copay for a typical generic drug is $10 a month, while its brand-name counterpart costs $50 a month, according to the Foundation for Advanced Education in the Sciences at the National Institutes of Health.

Generic substitutes

The share of prescriptions filled with generic drugs has increased to 82 percent in the last three months of 2013 from 60 percent in the first quarter of 2007, data from Bloomberg Industries show. CVS Caremark Corp., the largest provider of prescription drugs in the U.S., sees that rate rising to 85 percent by 2016.

Prescription drug prices rose 2.7 percent in February from a year earlier, down from 4.3 percent in the same month in 2012.

While patent expirations peaked in 2012, the trend toward heavier use of generic drugs continues to keep downward pressure on inflation, said Jason McGorman, a health-care analyst at Bloomberg Industries in Princeton, New Jersey.

AstraZeneca Plc loses U.S. patent protection in May for its acid-reflux medicine Nexium. At that point, Ranbaxy Laboratories Ltd., India’s largest drugmaker, is set to have six months of exclusive rights to produce a competing generic before more are allowed to flood the market, according to an e-mailed statement from Vanessa Rhodes, a spokeswoman for London-based AstraZeneca.

Nexium generated $3.9 billion in sales last year as AstraZeneca’s second best-selling drug.

Global spending on drugs will continue a shift toward generics, which will rise to 36 percent of total sales by 2017 from 27 percent in 2012, according to data from the Danbury, Connecticut-based IMS Institute for Healthcare Informatics.

Economists see PPACA taking over as the most important influence in pushing down prices in the year ahead as the effects of Medicare cuts and expiring drug patents recede. Thirteen of the 24 economists surveyed by Bloomberg said PPACA will play a primary role in reducing the prices insurers pay health-care providers.

“Even if there’s a rise in cost, I don’t think it’ll be very large,” McGorman said. “They’ll be trying to do everything they can to keep those costs down.”

–With assistance from Catarina Saraiva, Chris Middleton and Jeff Kearns in Washington and Allison Connolly in London.

See also:


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.